Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 195.00 | |
5 mg | In stock | $ 430.00 | |
10 mg | In stock | $ 636.00 | |
25 mg | In stock | $ 987.00 | |
50 mg | In stock | $ 1,360.00 | |
100 mg | In stock | $ 1,830.00 | |
500 mg | In stock | $ 3,680.00 |
Description | Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia. |
Synonyms | L0081, F-12511 |
Molecular Weight | 469.72 |
Formula | C29H43NO2S |
CAS No. | 202340-45-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15 mg/mL (31.93 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Eflucimibe 202340-45-2 Metabolism Acyltransferase L-0081 L 0081 L0081 F-12511 F 12511 F12511 inhibitor inhibit